trending Market Intelligence /marketintelligence/en/news-insights/trending/eF1vcbKHV2gyL_VRBrj5uw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

UK's NICE recommends Merck KGaA's head/neck cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UK's NICE recommends Merck KGaA's head/neck cancer drug

The U.K.'s National Institute for Health and Care Excellence recommended Merck KGaA's cancer drug Erbitux for routine use under the National Health Service.

Erbitux is used in combination with platinum-based chemotherapy for treating patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The treatment has been available in England through the U.K.'s cancer drugs fund since 2010.

The decision confirms the positive benefit the drug can have on the survival of patients, Germany-based Merck said in a news release. The recommendation also secures access to Erbitux for new patients in England with oral cavity tumors.